Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/AS01

Trial Profile

A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/AS01

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RH 5.1 (Primary) ; AS01B
  • Indications Falciparum malaria
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 28 Jul 2021 New trial record
  • 21 Apr 2021 According to an ExpreS2ion Biotechnologies Media Release, the study was funded by Leidos Inc. as part of the company's prime contract with the United States Agency for International Development (USAID) for the creation and testing of malaria vaccines.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top